Glenmark Expands U.S. Injectable Portfolio with Launch of Generic Lacosamide Injection
Glenmark Pharmaceuticals Ltd. has announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials in the United States market. The product is the generic equivalent of Vimpat Injection marketed by UCB Inc. and is indicated for the treatment of seizures associated with epilepsy.











